|
|
 Previous Article | Table of Contents | Next Article 
Hypermetaphase fluorescence in situ hybridization for quantitative
monitoring of Philadelphia chromosome-positive cells in patients with
chronic myelogenous leukemia during treatment
DC Seong, HM Kantarjian, JY Ro, M Talpaz, J Xu, JR Robinson, AB Deisseroth, RE Champlin and MJ Siciliano
Department of Hematology, University of Texas M.D. Anderson Cancer Center,
Houston 77030, USA.
Using Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia
(CML) as a model, our aim has been to develop a molecular cytogenetic
method of high resolution analysis for monitoring the frequency of cells
with nonrandom chromosome rearrangements in the bone marrow of patients
receiving treatment for hematologic malignancies. Long-term exposure (24
hours) of bone marrow cultures to colcemid (0.1 microgram/mL) maximized a
high frequency of metaphase collection. Such preparations were subjected to
fluorescence in situ hybridization (FISH) using a 5 Mb probe that
overlapped the region of the translocation at chromosome 9q34. This
detected the Ph translocation in the resultant large number of overly
contracted chromosome spreads. The procedure was validated and verified by
studying 70 double-blind marrow samples from patients in different stages
of Ph+ CML and from patients with Ph- hematologic malignancies (controls).
This hypermetaphase FISH (HMF) method clearly identified Ph+ metaphases and
allowed the analysis of 500 hypermetaphases per sample in less than 1 hour
after FISH. HMF (1) identified statistically significant differences
between the frequencies of Ph+ cells in samples that differed by less than
4%; (2) resolved such differences among patient samples that were all
judged 100% Ph+ by standard G-band cytogenetics (CG); (3) resulted in the
reclassification of response status in 23% of the patients initially
classified by CG; (4) recognized Ph+ cells in 16% of patients characterized
as having a complete cytogenetic response and in one patient with an
original diagnosis of Ph- CML; and in one patient with an original
diagnosis of Ph- CML; and (5) was informative where insufficient metaphases
were obtainable for analysis by CG. HMF appears to be uniquely suitable for
monitoring the status of patients with CML receiving treatment. It should
also be applicable for patients with any hematologic diseases where
chromosomal alterations are known and appropriate FISH probes are
available.
Volume 86,
Issue 6,
pp. 2343-2349,
09/15/1995
Copyright © 1995 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
H. Kantarjian, C. Schiffer, D. Jones, and J. Cortes
Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods
Blood,
February 15, 2008;
111(4):
1774 - 1780.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-M. Seong, S. Giralt, H. Kantarjian, J. Xu, J. Swantkowski, K. Hayes, A. B. Glassman, I. Khouri, M. Korbling, P. Thall, et al.
Early Detection of Relapse by Hypermetaphase Fluorescence In Situ Hybridization After Allogeneic Bone Marrow Transplantation for Chronic Myeloid Leukemia
J. Clin. Oncol.,
May 9, 2000;
18(9):
1831 - 1836.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Faderl, M. Talpaz, Z. Estrov, and H. M. Kantarjian
Chronic Myelogenous Leukemia: Biology and Therapy
Ann Intern Med,
August 3, 1999;
131(3):
207 - 219.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Faderl, M. Talpaz, Z. Estrov, S. O'Brien, R. Kurzrock, and H. M. Kantarjian
The Biology of Chronic Myeloid Leukemia
N. Engl. J. Med.,
July 15, 1999;
341(3):
164 - 172.
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Buno, W. A. Wyatt, A. R. Zinsmeister, J. Dietz-Band, R. T. Silver, and G. W. Dewald
A Special Fluorescent In Situ Hybridization Technique to Study Peripheral Blood and Assess the Effectiveness of Interferon Therapy in Chronic Myeloid Leukemia
Blood,
October 1, 1998;
92(7):
2315 - 2321.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
